Keep up-to-date on the latest vision-related news and eye care events in our Practice.
We will be doing some posts on education & advocacy around the healthcare space. If you are a patient of Danville Family Eye Care, you will know that we believe in practicing full scope optometry. What this means is that we believe your eyes and your vision can say a lot about your health. The eyes are one place in the body where we can see what is happening on the inside. Dr. Allen and Dr. Blazek can view the blood vessels and nerves in real time - without doing anything invasive - and see if there are signs of systemic health conditions, such as diabetes, hypertension, autoimmune diseases, and certain types of cancer. Both doctors actively treat patients with glaucoma, dry eye disease, and will monitor / manage other conditions such as diabetic retinopathy and macular degeneration.
It is for this reason, our team does keep tabs on what is happening in the overall healthcare space. Some trends, such as the rise of private equity is happening in several specialties, not just vision care. As many of you may have experienced, pharmacy benefits managers (PBMs) also play a huge role in what medications are available to treat patients, not only for ocular conditions such as glaucoma, but in the whole healthcare space. Many doctors are getting frustrated and burned out from the increased administrative time it is takes to jump through each individual insurance plans hoops to perform necessary testing, or prescribe the best medication to treat a patient.
For now, we are going to post those items here in our What's New blog. However it is possible in the future that we will set up a subpage specifically for this type of information, along with resources to make sure we all stay informed.
One link that we would like to share came from a Review of Optometry journal. You can click on the link, or view the copied post below:
Why Pricey Prescriptions are Here to Stay
The Inflation Reduction Act doesn't address the main cause: PBMs.
By Paul M. Karpecki, OD, Chief Clinical EditorPublished October 15, 2022 Patients and prescribers have no interaction with pharmacy benefit managers (PBMs), yet these administrators usually take home more than half of the money generated from each Rx filled. They serve as middlemen to “negotiate” with pharmaceutical companies for placement on an insurance formulary. Three PBMs have an oligopoly, accounting for more than 80% of the category: CVS Caremark, Express Scripts and OptumRx.
While these groups claim to help lower drug costs, prices continue to escalate. Why? To capitalize on their position, PBMs will pay and work incestuously with insurance companies, which sometimes even own the PBMs.
How Does the Scheme Work?
These middlemen collect billions of dollars in rebates for prioritizing pharmaceutical agents on tiered formularies. Then, they pay the insurance companies and hospitals, being sure to keep a sizable share for themselves. This pay-to-play approach fails to take drug efficacy or patient needs into account.
If drug companies refuse to pay these fees—which can constitute 60% of the entire cost of the drug—the PBM will exclude them from the formulary entirely or assign them to a lower tier that challenges patient access, leaving overworked physicians to petition for them. This happens despite the fact that pharmaceutical companies are the ones spending billions on research and development for potentially life- and vision-saving treatments and fighting to have these drugs passed by the FDA. Greater transparency of the profit flow within this system would help shed light on its need for reformation.
PBMs Tied to Inflation
Here’s an example to illustrate how a patient may end up paying more for their drugs than the insurance companies do (thanks to PBMs). Let’s say a drug company provides a rebate of 80% on a drug priced at $500; thus, the company keeps $100. The logical move would be to charge $1,000, so that they can take home $200. Although the manufacturer might appear greedy, it’s the PBM receiving the much larger monetary portion of $800. The insurance companies then purchase and upcharge these drugs to get their cut, and so the cycle continues.
United Health Group’s 2022 second quarter revenues grew $9 billion, or 13%, to over $80 billion year-over-year, and its earnings exceeded $7 billion over the last three months. Fewer drugs are covered, making it harder for pharmacies to maintain profitability. Insurance companies create barriers that oblige pharmacies to increase prices, such as by denying drug coverage, mandating prior authorizations or requiring step-edits that order the use of a generic or cheaper drug first. This system often prevents patients from receiving a medication that would be superior or essential to their health.
We Can’t Ignore the Middlemen
The Inflation Reduction Act calls for policy improvements such as allowing Medicare to negotiate prices and help prevent PBMs from charging rebates on a few select drugs. However, the document doesn’t require PBMs to be transparent about what they make.
While it’s true we must address costs at every level, failing to include PBMs in the commercial payer space will continue to stand in the way of reducing inflation of drug prices. If PBMs decide they want an 85% rebate or more, drug companies won’t have the means to lower prices and continue developing drugs that save vision and lives.
Calling for Creative Solutions
If the government isn’t willing to require transparency, other avenues to dodge the middlemen need to be sought out. One company-, RVL Pharmaceuticals, has eliminated PBMs, insurance companies and pharmacies. The maker of Upneeq for ptosis offers a prescription at a set price through RVL Pharmacy, which also ensures the patient doesn’t encounter surprises (e.g., insurance denials, pre-authorizations or inflated costs).
Another creative solution that removes the middleman is allowing doctors to dispense medications from their offices, which is legal for optometrists and ophthalmologists in most states.
It’s time to look at the true reason for inflation in health care. Understanding the behind-the-scenes world of PBMs is essential to help keep medications accessible and affordable.
Dr. Karpecki is the director of Cornea and External Disease for Kentucky Eye Institute, associate professor at KYCO and medical director for the Dry Eye Institutes of Kentucky and Indiana. He is the Chief Clinical Editor for Review of Optometry and chair of the New Technologies & Treatments conferences. A fixture in optometric clinical education, he consults for a wide array of ophthalmic clients, including ones discussed in this article. Dr. Karpecki's full list of disclosures can be found here.
Healthy Optometry Promise for Everyone
Introducing H.O.P.E. Danville Family Eye Care's discount plan to bring clarity and true cost savings to your eye care needs. Starting "open enrollment" for the 2023 calendar year.
$150 per adult / $120 per child will provide an exam - including retinal screening, a 40% discount for eyeglasses, 25% discount on contact lens evaluations, and double the in-house rebate on contact lenses. No frequency limitations during the year. There are only a couple of exclusions on the eyeglass brands we carry. These discounts can be used for both glasses AND contact lenses for those that desire to purchase both in the same year. Most other vision plans allow discounts on just one or the other.